Skip to main content



IHV S218

Phone (Primary):


Download CV

Education and Training

Eleanor (Pitt) Wilson, a native of Louisville, Kentucky, attended medical school at the Johns Hopkins Medical Institute, in Baltimore, Maryland. She completed residency training in Internal Medicine at Vanderbilt University Medical Center in Nashville, Tennessee, and subspecialty fellowship training in Infectious Disease at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland. She obtained her Masters in Clinical Research as part of a collaborative program between Duke University and the National Institutes of Health.


Despite dramatic improvements in the life expectancy of persons with human immunodeficiency virus (HIV) infection, non-AIDS events such as liver disease and cancer are now the predominant causes of morbidity and mortality in treated populations. Markers of immune activation have been associated with HIV disease progression, predict mortality, and persist despite effective antiretroviral therapy; patients co-infected with hepatitis C virus (HCV) and HIV have higher levels of immune activation than those infected with HIV or HCV alone and are at increased risk for mortality due to liver and cardiovascular disease. Understanding the role of immune activation in the rapid progression of hepatic fibrosis in patients with HIV and HCV co-infection will help us to address this burgeoning public health problem, and at the same time, understand how the clearance of a chronic viral infection affects global immune activation and what can be done to augment treatment responses and improve rates of viral clearance and resolution of hepatic fibrosis.

My scientific interests and investigations have focused on the alterations to innate and adaptive immunity in chronic viral infections, including HIV and viral hepatitis. Beginning with my work with Dr. Robert Siliciano during medical school investigating HIV persistence in latently infected T cell subsets, extending through my fellowship research with Dr. Irini Sereti regarding the mechanisms connecting soluble and cellular immune activation with clinical outcomes in HIV, and now working with Dr. Shyam Kottilil on the reconstitution of innate and adaptive immunology following clearance of HCV, I have developed expertise in the translational research techniques required to address these questions. As a Principal Investigator and Lead Associate Investigator on multiple clinical trials in the beginning of my career at the National Institute of Allergy and Infectious Diseases and now at the Institute of Human Virology, I am eager to continue working on ways to improve the health of patients with chronic viral infections and advanced liver disease.

Research/Clinical Keywords

Hepatitis C therapeutics, long term outcomes, viral resistance, and retreatment options HIV/AIDS Hepatitis B therapeutics Solid Organ Transplant Infectious Disease

Highlighted Publications

Shen, L, S Peterson, AR Sedaghat, MA McMahon, M Callender , H Zhang, Y Zhou Y, E Pitt, KS Anderson, EP Acosta, RF Siliciano. “Dose-response curve slope sets class-specific limits on inhibitor potential of anti-HIV drugs,” in Nature Medicine (2008); 14(7):762-6.

Wilson, E*; S Krishnan*; V Sheikh, A Rupert, D Mendoza, J Yang, R Lempicki, SA Migueles, and I Sereti. “Evidence for innate immune system activation in HIV-1 infected elite controllers,” JID (2014);209(6):931-9.

Wilson, E and I Sereti. “Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs,” Immunological Reviews (2013); 254(1):343-54.

Baker, JV, KH Hullsiek, A Singh, E Wilson, WK Henry, K Lichtenstein, N Onen, E Kojic, P Patel, JT Brooks, HN Hodis, M Budoff, I Sereti for the CDC SUN Study Investigators. “Immunologic Predictors of Coronary Artery Calcium Progression in a Contemporary HIV Cohort” AIDS (2014);28(6):831-40.

Wilson, E, A Singh, KH Hullsiek, D Gibson, WK Henry, K Lichtenstein, N Onen, E Kojic, P Patel, JT Brooks, I Sereti and JV Baker for the CDC SUN Study Investigators. “Monocyte Activation Phenotypes Are Associated with Biomarkers of Inflammation and Coagulation in Chronic HIV Infection,” JID (2014); 210(9):1396-406.

Kohli A, S Kattakuzhy,S Sidharthan, A Nelson, M McLaughlin, C Seamon, E Wilson, E Meissner, Z Sims, RSilk, C Gross, A Price, TA Jolley, MProschan,GTeferi, JChavez, S Abbott, A Osinusi, H Mo, MA Polis,HMasur, S Kottilil, “Safety and efficacy of four-week directly acting anti-HCV regimens in HCV genotype-1 patients without cirrhosis: a phase 2a trial,” Annals Int Med (2015);163(12):899-907.

Wilson, E, S Kattakuzhy, S Sidharthan, Z Sims, L Tang, M McLaughlin, A Price, A Nelson, R Silk, C Gross, E Akoth, H Mo, GM Subramanian, PS Pang, JG McHutchison, A Osinusi, H Masur, A Kohli, S Kottilil. “Successful Retreatment of Chronic HCV Genotype-1 Infection with Ledipasvir and Sofosbuvir After Initial Short Course Therapy with Direct-Acting Antiviral Regimens,” CID (2016);62(3):280-8.

Kattakuzhy, S, E Wilson, S Sidharthan, Z Sims, M McLaughlin, A Price, R Silk, C Gross, E Akoth, M McManus, B Emmanuel, S Shrivastava, L Tang, G Teferi, J Chavez, B Lam, H Mo, A Osinusi, M Polis, H Masur, A Kohli, S Kottilil. “Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease,” CID (2016);62(4):440-7.

Wilson, E, L Tang, S Kottilil. “Eradication Strategies For Chronic Hepatitis B Infection,” CID (2016);62(S4):S318-25.

Wilson, E, E Rosenthal, S Kattakuzhy, L Tang, S Kottilil, “Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C,” accepted by Clin Micro Rev. 2016, DOI: pending.

Additional Publication Citations


Pitt, E; CM Haggerty, and RF Siliciano. “The Latent Reservoir for HIV-1 in Resting CD4+ T cells and Other Viral Reservoirs during Chronic Infection: Insights from Treatment and Treatment Interruption Trials” in Curr Op HIV/AIDS (2006);1(1):62-68.


Siliciano, JD, J Lai, M Callender, E Pitt, H Zhang, JB Margolick, JE Gallant, J Cofrancesco Jr, RD Moore, SJ Gange, RF Siliciano. “Stability of the Latent Reservoir for HIV-1 in Patients Receiving Valproic Acid,” in JID (2007);195(6):833-6.


Wu, PA; ML Turner, EW Cowen, E Wilson; YR Shea, T Jancel, AF Freeman. “Sixty-year-old man with slowly expanding nodular plaque on the thigh,” in J Am Acad Dermatol (2010);63:1083-7.


Moriyama, B; M Ditullio, E Wilson, S Henning, S Penzak, R Danner, A Zelazny, J Gea-Banacloche, J Barrett. “Pharmacokinetics of Anidulafungin in Pleural Fluid During the Treatment of a Patient with Candida Empyema,” in Antimicrob Agents and Chemother, 2011 May;55(5):2478-80.


Wilson, E, T Tanzosh, F Maldarelli. “HIV diagnosis and testing: what every healthcare professional can do (and why they should),” Oral Diseases (2013);19(5):431-9.


Sheikh, V; M Caplan, E Wilson, B Papadi, A Rosenberg, J Higgins, B Driscoll, A Filie, I Sereti. “CMV IRIS manifesting as sialadenitis in an HIV-infected patient,” AIDS (2013);27(11):1833-5.


Sereti, I, J Estes, W Thompson, M Fischl, T Croughs, S Beq, S Lafaye de Micheaux, M Yao, A Ober, E Wilson, V Natarajan, H Imamichi, M Boulassel, M Lederman, and JP Routy. “Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration,” PLoSPathogens (2014);10(1):e1003890.


Wilson, E, KH Hullsiek, I Sereti and JV Baker. “Reply to Bandera et al,” JID (2015); 212(5):841-2.


Tang, L, S Kattakuzhy, E Wilson, S Kottilil. “Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection,” Expert Rev of Gastro & Hepat (2016);10(1):21-36.


Kattakuzhy, S, R Levy, E Rosenthal, L Tang, E Wilson, S Kottilil. “Hepatitis C genotype 3 disease,” Hepatol Int (2016); epub ahead of print, DOI: 10.1007/s12072-016-9748-z.


Desimmie, B, R Burdick, T Izumi, H Doi, W Shao, W Alvord, K Sato, Y Koyanagi, S Jones, E Wilson, S Hill, F Maldarelli, W Hu, V Pathak. “APOBEC3 proteins can copackage and comutate HIV-1 genomes,” accepted by Nucleic Acids Res. 2016, DOI: pending.


Research Interests

Clinical virology, including HIV and HCV viral drug resistance

Hepatitis C therapeutics, including investigational therapeutics, retreatment strategies, and therapy in the setting of liver transplantation

Hepatitis B therapeutics, including investigational therapeutics and treatment strategies

Immune activation associated with chronic viral infections, particularly in the setting of HIV and HCV co-infection

Clinical Specialty Details

Hepatitis C therapeutics, long term outcomes, viral resistance, and retreatment options
Hepatitis B therapeutics
Solid Organ Transplant Infectious Disease

Edit Icon - Click to update your profileUpdate Your Profile